The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions. Associations between PIK3CA mutations and reduced survival are identified in three subgroups of ER-positive cancer (defined by amplification of ...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of ...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
International audienceWe analysed whole-genome sequences of 560 breast cancers to advance understand...
We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver muta...
International audienceWe analysed whole-genome sequences of 560 breast cancers to advance understand...
This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary br...
This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary br...
SummaryThis study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pat...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of ...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are imp...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
International audienceWe analysed whole-genome sequences of 560 breast cancers to advance understand...
We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver muta...
International audienceWe analysed whole-genome sequences of 560 breast cancers to advance understand...
This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary br...
This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary br...
SummaryThis study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pat...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer cl...
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of ...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...